+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2018

  • ID: 4667879
  • Drug Pipelines
  • November 2018
  • Region: Global
  • 123 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Akero Therapeutics Inc
  • Bayer AG
  • Eddingpharm Inc
  • Eli Lilly and Co
  • Genosco Inc
  • Incyte Corp
  • MORE
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2018

Summary

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades.

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 4, 6, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Type 2 Diabetes, Esophageal Cancer, Melanoma, Nasopharyngeal Cancer, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Ovarian Cancer, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Achondroplasia, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bladder Cancer, Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, High-Grade Glioma, Liver Cancer, Lymphoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Primitive Neuroectodermal Tumor (PNET), Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Spinal Cord Injury, Squamous Cell Carcinoma, Thymic Carcinoma and Thyroid Cancer.

The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Akero Therapeutics Inc
  • Bayer AG
  • Eddingpharm Inc
  • Eli Lilly and Co
  • Genosco Inc
  • Incyte Corp
  • MORE
Introduction

Report Coverage

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Abbisko Therapeutics Co Ltd

Akero Therapeutics Inc

ArQule Inc

Bayer AG

Blueprint Medicines Corp

Eddingpharm Inc

Eisai Co Ltd

Eli Lilly and Co

Everest Medicines Ltd

Genosco Inc

H3 Biomedicine Inc

Hanmi Pharmaceuticals Co Ltd

Incyte Corp

InnoCare Pharma Ltd

Johnson & Johnson

NGM Biopharmaceuticals Inc

Principia Biopharma Inc

Vichem Chemie Research Ltd

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles

ABSK-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKR-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-9931 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

derazantinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDP-317 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erdafitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ES-135 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FGF-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

golvatinib tartrate + lenvatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-3B6527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-81442 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICP-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-62079 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infigratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenvatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-2874455 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRN-1371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rogaratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit FGFR4 for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Oct 25, 2018: Eisai to present latest data on Lenvima (lenvatinib) and Keytruda (pembrolizumab) combination and exploratory research on a structurally novel class of sting agonist at 33rd SITC annual meeting

Oct 24, 2018: Eisai to present latest data on LENVIMA (lenvatinib) and KEYTRUDA (pembrolizumab) combination at SITC's 33rd Annual Meeting

Oct 19, 2018: QED Therapeutics presents data for Infigratinib in Cholangiocarcinoma in late breaking abstract at the European Society of Medical Oncology 2018 Congress

Oct 10, 2018: Janssen to present on Erdafitinib at ESMO 2018

Oct 10, 2018: Eisai to present Lenvatinib at ESMO 2018 congress

Oct 09, 2018: Bayer to showcase latest oncology research on rogaratinib at ESMO 2018 Congress

Sep 18, 2018: Janssen submits New Drug Application to U.S. FDA seeking approval of Erdafitinib for the treatment of Metastatic Urothelial Cancer

Sep 11, 2018: NICE issues evidence-based recommendations on Lenvatinib for treatment of differentiated thyroid cancer

Sep 11, 2018: Andrew Cheng, MD, PhD joins Akero Therapeutics as President and Chief Executive Officer

Sep 05, 2018: Eisai and Merck announce China National Medical Products Administration (nmpa) approval of lenvima (lenvatinib) for treatment of unresectable hepatocellular carcinoma (hcc)

Aug 29, 2018: Lenvima (lenvatinib) capsules approved for first-line treatment of unresectable hepatocellular carcinoma (HCC) in South Korea

Aug 23, 2018: European Commission grants marketing authorization for LENVIMA (lenvatinib) as first-line treatment in adults with advanced or unresectable hepatocellular carcinoma

Aug 16, 2018: Eisai And Merck Announce FDA Approval Of LENVIMA (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)

Jul 31, 2018: Eisai and Merck, Kenilworth USA announce U.S. FDA grants breakthrough therapy designation for LENVIMA in combination with KEYTRUDA

Jun 29, 2018: CHMP recommends extension of indications for Lenvima

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Products under Development by Companies, H2 2018 (Contd..6), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Abbisko Therapeutics Co Ltd, H2 2018

Pipeline by Akero Therapeutics Inc, H2 2018

Pipeline by ArQule Inc, H2 2018

Pipeline by Bayer AG, H2 2018

Pipeline by Blueprint Medicines Corp, H2 2018

Pipeline by Eddingpharm Inc, H2 2018

Pipeline by Eisai Co Ltd, H2 2018

Pipeline by Eli Lilly and Co, H2 2018

Pipeline by Everest Medicines Ltd, H2 2018

Pipeline by Genosco Inc, H2 2018

Pipeline by H3 Biomedicine Inc, H2 2018

Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018

Pipeline by Incyte Corp, H2 2018

Pipeline by InnoCare Pharma Ltd, H2 2018

Pipeline by Johnson & Johnson, H2 2018

Pipeline by NGM Biopharmaceuticals Inc, H2 2018

Pipeline by Principia Biopharma Inc, H2 2018

Pipeline by Vichem Chemie Research Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abbisko Therapeutics Co Ltd
  • Akero Therapeutics Inc
  • ArQule Inc
  • Bayer AG
  • Blueprint Medicines Corp
  • Eddingpharm Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Everest Medicines Ltd
  • Genosco Inc
  • H3 Biomedicine Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Incyte Corp
  • InnoCare Pharma Ltd
  • Johnson & Johnson
  • NGM Biopharmaceuticals Inc
  • Principia Biopharma Inc
  • Vichem Chemie Research Ltd
Note: Product cover images may vary from those shown
Adroll
adroll